Duodenal gastrointestinal stromal tumors: Review on clinical and surgical aspects  by Cavallaro, G. et al.
at SciVerse ScienceDirect
International Journal of Surgery 10 (2012) 463e465
REVIEWContents lists availableInternational Journal of Surgery
journal homepage: www.thei js .comReview
Duodenal gastrointestinal stromal tumors: Review on clinical and surgical aspects
G. Cavallaro a,*, A. Polistena b, G. D’Ermo b, G. Pedullà b, G. De Toma b
aDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University, Rome, Italy
bDepartment of Surgery “P. Valdoni”, Sapienza University, Rome, Italya r t i c l e i n f o
Article history:
Received 13 June 2012
Received in revised form
14 August 2012
Accepted 21 August 2012
Available online 30 August 2012
Keywords:
Duodenal tumors
GIST* Corresponding author.
E-mail address: giuseppe.cavallaro@uniroma1.it (G
1743-9191/$ e see front matter  2012 Surgical Asso
http://dx.doi.org/10.1016/j.ijsu.2012.08.015a b s t r a c t
Introduction: Gastrointestinal stromal tumors (GISTs) arising in the duodenum represent a rare entity and
can be very demanding to manage. The diagnosis can be difﬁcult (as these tumors can be misdiagnosed
as pancreatic head tumors), and to treat owing to the complex anatomy of the duodenum and of the
pancreatic head. Complete resection may require extensive procedures such as
pancreaticodudodenectomy.
Methods and results: An extensive literature review regarding clinico-pathological features, diagnostic
investigations and surgical options in the management of duodenal GISTs has been performed.
Conclusions: Duodenal GISTs have uncertain malignant potential, and they may be asymptomatic, or
present with abdominal pain or bleeding. A preoperative diagnosis can be difﬁcult to obtain. Endoscopic
ultrasound and ﬁne needle aspiration cytology (FNAC) may be helpful. Surgical R0 resection remains the
only curative approach. However, owing to the complex anatomy of the duodenum, limited resection is
not always feasible. In these cases, extensive procedures such as pancreaticoduodenectomy or pancreas-
preserving duodenectomy are the treatment of choice.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastrointestinal stromal tumors (GISTs) represent the most
common tumor of mesenchymal origin arising in the gastrointes-
tinal tract (GI tract).1,2 They often express c-kit protein and react
with CD-117 antibody.1,2 These tumors can arise everywhere in the
GI tract, even though they are more frequently found in the
stomach (about 60%), small bowel (about 25%), colon and rectum
(about 10%), while only 3e5% of GISTs occur in the duodenum.
There are only sporadic reports of extra-gastrointestinal stromal
tumors (e-GISTs) arising in the omentum, mesentery or retro-
peritoneum.2e4
The duodenum represents a very rare location for GISTs.
Owing to the complex anatomy of the duodeno-pancreatic
region, these tumors are often challenging in diagnosis (can be
misdiagnosed as pancreatic head tumors), and in surgical
management as radical resection may require extensive proce-
dures such as pancreaticodudodenectomy.5,6 Several studies have
proposed to identify clinical and diagnostic features, as well as
prognostic factors and therapeutic options for these rare
tumors.6e10. Cavallaro).
ciates Ltd. Published by Elsevier Lt2. Clinico-pathologic features
Most GISTs occur sporadically; about 5e10% occur in hereditary-
familial syndrome (type I Neuroﬁbromatosis, Carney triad).2,5
The clinical presentations of duodenal GISTs are highly variable,
and they are related to their origin, growth (intramural or extra-
mural), and size.6,10 The most common clinical presentations are
gastrointestinal bleeding (whenmucosal ulceration is present), and
abdominal pain.3,7,11 These tumors are often diagnosed incidentally,
as they can be asymptomatic, especially for small tumors, or when
the tumor growth is extraluminal.8,10 Some authors described back
pain, jaundice (compression of common bile duct), or bowel
obstruction, but these events are very rare.8,11
At diagnosis, most authors report a smaller size tumor (4.0e
5.0 cm) for duodenal GISTs when compared with gastric or small
bowel GISTs.8,10,11 However, this is still controversial,12 as these
tumors are rare.
Histologically duodenal GISTs do not differ from other GITSs.
These tumors usually present with spindle cell differentiation,
which is more frequent than epithelioid cell differentiation or
mixed types. There is no apparent correlation between histologic
subtype and risk of tumor recurrence.5,12
The mitotic count has been found to be lower in duodenal GISTs,
with a median count <5/50 HPF,3,8,9 which is lower than gastric and
small bowel tumors (where a mitotic count >5/50 HPF has beend. All rights reserved.
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REVIEWfound inmore than30%of cases).13e15However, thesedataneed to be
interpreted carefully due to the small number of tumors examined.
As described in the medical literature, GISTs in the duodenum
do not differ from other GISTs in immunohistochemical reaction.
Most of them express CD-117 (c-kit) and CD-34,3,8,9 which has been
found to be associated with worse prognosis.9 PDGFRA expression
is less frequent, and there is no relation to a different prognosis.
Systematic analysis of ki-67, p53 and p16 expression can prob-
ably identify cases with different prognoses, but there is still lack of
data on this. It seems that duodenal GISTs differ from other GISTs
(gastric and small bowel) in the expression of these prognostic
factors.8 Some authors have reported on a lower prevalence of p16
loss and ki-67, which are both considered as indicators of poorer
prognosis.8 However, these data need to be conﬁrmed by larger
series, and there is a probability that a more benign behavior was
related to the smaller size and lower mitotic count at diagnosis.
For these reasons, duodenal GISTs usually have better prognosis
as compared with gastric and small bowel GISTs. According to the
NIH risk stratiﬁcation, they are more frequently identiﬁed as very
low risk and low risk tumors (about 60e70% of reported duodenal
GISTs have been classiﬁed as very low or low risk tumors).8,10
The size at diagnosis, prognostic indicators, and risk stratiﬁca-
tion of duodenal GISTs should guide the surgeon to a limited
resection, which should always be a R0 resection. However, up to
now, there is still lack of knowledge on the preoperative indicators
of bad prognosis and high risk of recurrence.
3. Preoperative diagnosis
Gastrointestinal endoscopy remains themost commondiagnostic
procedure in duodenal GISTs, especially in patients with intramural
growth or mucosa ulceration and bleeding.8,10 It allows forceps
biopsy, which is not helpful in extraluminal tumor. In the latter, the
most used diagnostic test remains CT scan or MRI. On CT, GISTs are
hypervascular with cystic and necrotic components. Smaller tumors
appear as sharplymarginated smoothmasses, withmoderate to high
contrast enhancement,10,16,17 while larger masses show central
necrosis and cavitation, with heterogeneous contrast enhancement.
MRI ﬁndings of GIST are extremely variable, depending on tumor
necrosis, hemorrage and cavitation, which can affect signal inten-
sity.10,18 Usually, the solid portions of GIST show low signal intensity
on T1-weighted images and high signal intensity on T2-weighted
images, and are enhanced after gadolinium administration.18
The difﬁculties in preoperative diagnosis make a preoperative
diagnosis of GIST rare. In most cases, GISTs is only “suspected”.
Recently, endoscopic ultrasound (EUS) has been found to be very
helpful for esophago-gastro-duodenal GISTs, with high sensitivity
and speciﬁcity rates.19,20 Furthermore, EUS is also capable of guiding
ﬁne needle aspiration (FNA) under real-time ultrasound using
a through-the-scope needle aspiration device20e22 to obtain speci-
mens for cytologic examination and immunocytochemical evalua-
tion for CD-117 and CD-34 positivity.20,23 EUS-guided FNA cytology
with immunocytochemical evaluation can diagnose GIST in up to
80% of patients 20. This procedure has its limitation on the prediction
of malignancy, as cytologic atypia and high mitotic activity do not
always predict the malignant behavior of the tumor.19,20 Predictions
on the potential aggressiveness of GIST are best reserved for
histology or, better, the patient’s ultimate outcome.
4. Surgical treatment
4.1. Which is the treatment of choice for duodenal GISTs?
First, we should aim at a complete surgical resection with clear
margins (R0 resection).7,11,24 Second, as submucosal spread, andlocal lymph node involvement are infrequent for GISTs, wide
resection margins with routine lymph node dissection are not
necessary as for epithelial tumors.10,24
There is no consensus on the optimal surgical treatment for
GISTs arising from the duodenum.10,11 Operations which vary from
tumor enucleation (for extramural GISTs) to pan-
creaticoduodenectomy for inﬁltrating or larger tumors have been
advocated.3,6,8
Limited resections (LR) can be performed in small tumors not
inﬁltrating the surrounding structures, and when the papilla of
Vater can be preserved.3,7 In large series, duodenal wedge resection
has been performed for small tumors (1e2 cm in diameter) which
were located on the duodenal wall at least 2 cm from the papilla, so
that a safe resection and anastomosis can be carried out with
minimal risk of stenosis.3,7,8 Recently, a mini-invasive (laparo-
scopic) approach has been reported on tumor enucleation and on
duodenal wedge resection, with good perioperative and long-term
results.10 Segmental duodenectomy, with end-to-end or side-to-
end duodeno-jejunal anastomosis can be performed for larger
tumors which are located below the papilla of Vater in the third or
fourth duodenal portions.3,5,7,25 Recently, partial duodenectomy
with a Roux-en-Y duodeno-jejunal anastomosis has been proposed
for large tumors which involved the antimesenteric border of the
second and third portions of the duodenum, in order to avoid
carrying out pancreaticoduodenectomy.7
Limited resection should only be done when the resection
achieves histologically clear margins (R0) and preserves the
common bile duct and the papilla of Vater, with an acceptably low
risk of perioperative complications. Otherwise pan-
creaticoduodenectomy (or the technically more demanding
pancreas-sparing duodenectomy) should be performed.3,5,6
Limited resections are more likely to contribute to a better
quality of life, functional preservation of the pancreas, and conti-
nuity of the gastrointestinal tract. Furthermore, the difﬁculties in
performing pancreaticoduodenectomy in these cases are due to the
small caliber of the common bile duct and of the pancreatic duct, so
that reconstruction can be very demanding, with increased risks of
anastomotic leak and stenosis.3,7,10
The main concern on limited resection is the theoretical
increased risk of tumor recurrence. As malignancy is not estab-
lished at the time of surgery in most cases, the data in the medical
literature are not conclusive. The data seems to suggest that local
recurrence is inﬂuenced by the presence of positive resection
margins,3,7,11 but not by the kind of surgical resection (limited
resection vs. pancreaticoduodenectomy), as the two procedures
had similar disease-free survival rates.7 There is also a tendency to
perform pancreaticoduodenectomy for large tumors which have
a higher risk of malignancy and recurrence, and limited resection
for small tumors which have a benign behavior. The disease-free
survival rate at 1e3 years after surgical complete resection, in all
kinds of resection, has been reported to vary from 86 to 100%,9,10
indicating that duodenal GISTs have a slightly more favorable
prognosis than gastric or small bowel GISTs.
5. Imatinib mesylate
Imatinib mesylate, a tyrosine kinase inhibitor, plays a key role in
the management of GISTs. Its use in neoadjuvant therapy, adjuvant
therapy and in tumor recurrence26,27 has dramatically changed the
natural history of metastatic and recurrent GISTs.
In the neoadjuvant setting for GISTs located in the second
portion of the duodenum, Imatinib mesylate has been used for
tumor downstaging in order to perform a less extensive surgery
with free resection margins.9 However, this requires a precise
preoperative diagnosis of GIST which is not always easy to obtain.
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recurrence of duodenal GIST, should not differ from that for other
GISTs, and the treatment should be continued indeﬁnitely (usually
at a dose of 400 mg/day). Interruption of treatment is generally
followed by rapid tumor progression.9,28 The major limitation of
Imatinib is the development of tumor resistance, which is related to
the acquisition of additional c-kit mutations.26
6. Conclusions
Duodenal GISTs are uncommon tumors with uncertain malig-
nant potential. The presentation may be asymptomatic or the
patient can present with abdominal pain or bleeding. Preoperative
diagnosis can be difﬁcult to obtain. These tumors often present as
duodeno-pancreatic hypervascular masses, which are not easy to
distinguish from other tumors such as pancreatic adenocarcinoma.
Endoscopic ultrasound and FNA cytology may be helpful in the
preoperative setting. Surgical R0 resection remains the only cura-
tive treatment. Due to the complex anatomy of the duodenum,
limited resections (wedge resection, enucleation, segmental duo-
denectomy) are not always feasible, especially in tumors larger
than 3 cm, or when the tumor involves the second portion of the
duodenum (and the papilla of Vater). Pancreaticoduodenectomy
(or pancreas-preserving duodenectomy) is the treatment of choice
for these patients, even if these tumors usually have a low risk of
malignancy when compared with gastric or small bowel GISTs.
Due to the rarity, there are still controversies on the manage-
ment and behavior of duodenal GISTs.
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